Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows the ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.

Generally, the invention is in relation to the field of drug delivery devices to augment standard radiation therapy and methods of making and using same. Specifically, this technology utilizes a controlled release of drug from a coated balloon for local intratumoral drug delivery to breast tissue to supplement or replace standard radiation therapy.

A wound dressing product that includes a substrate layer having an upper surface and a lower surface; a tacky silicone coating composition present on the upper surface and on the lower surface; and upper and lower release sheets covering the substrate and the tacky silicone coating composition on the upper and lower surfaces, respectively, and adhered to the surfaces by the tacky silicone coating composition, wherein the upper surface is less tacky than the lower surface whereby the upper release sheet can be removed from the upper surface more readily than the lower release sheet can be removed from the lower surface. Also provided are methods for making such dressings.

A medical device wherein the device has an outer surface coated with an oleophilic lubricous coating or the device is formed from a mixture including a polymer and an oleophilic compound.

This invention discloses a method for stabilizing bioactivity of a growth factor, including mixing collagen with a growth factor and freeze drying the mixture to remove water. After this treatment, the bioactivity of the growth factor at room temperature remains stable for at least 7 days.

A biological scaffold in the present invention comprises a main body, a biological material layer, and an optional tissue adhesive layer. The main body at least has a non-constituted collagen matrix. The biological material layer is coated at least on a surface of the main body, and the tissue adhesive layer is disposed at least on another surface of the main body. When the biological scaffold is adhered to a tissue through the tissue adhesive layer, a plurality of cells move from the tissue to either the adhesive layer or the biological material layer for tissue repairing or regeneration.

Implantable medical devices coated with multiple atomic layers of amorphous titanium dioxide applied by atomic layer deposition have improved mammalian cell adhesion and inhibition of bacterial growth. Thickness of the coating can be used to tune resorption of bioresorbable vascular scaffolds for treatments of cardiovascular disease.

A bone implant for enclosing bone material is provided. The bone implant comprises a covering, which can be a biodegradable mesh. The covering is configured to be rolled into a diameter to at least partially enclose the bone material within the covering. In some embodiments, the covering includes a body portion and a closure portion adjacent to the body portion. The closure portion is configured to hold the covering in a rolled configuration to a predetermined diameter to at least partially enclose the bone material. A kit and a method of using the bone implant are also provided.

Medical device products have a coating with NAMSA Class VI certification and properties corresponding to the prior art coatings within U.S. Pat. No. 10,604,660. Medical device processes use the medical device product having a coating with NAMSA Class VI certification and properties corresponding to the prior art coatings within U.S. Pat. No. 10,604,660.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.